Keyphrases
Glioblastoma
100%
Neoantigen
60%
Radiation Therapy
45%
Tumor
35%
Temozolomide
32%
Immunogenomics
31%
Checkpoint Blockade
28%
CD8+ T Cells
25%
Newly Diagnosed Glioblastoma
25%
Brain Tumor
24%
Overall Survival
23%
Listeria Monocytogenes
21%
Concurrent Radiation
20%
Progression-free Survival
19%
CD4+ T Cells
19%
Phase 1/2 Study
18%
Disulfiram
18%
Salmonella Infection
18%
Metastatic Melanoma
17%
Programmed Death-ligand 1 (PD-L1)
16%
GL261
16%
Pembrolizumab
15%
Recurrent Glioblastoma
15%
BRAF mutant
15%
Clinical Trials
15%
Salmonella
15%
Glioma Model
14%
High-grade Glioma
14%
Glioblastoma multiforme
14%
Targeted Therapy
13%
T Cells
13%
Protective Immunity
13%
Specific T Cells
12%
Intracranial Melanoma
12%
Isocitrate Dehydrogenase 1 (IDH1)
12%
Phase II Study
12%
CD4+ T
12%
Doxorubicin
12%
Brain Microenvironment
12%
Photothermal Therapy
12%
Tumor Growth
12%
TERT Promoter mutation
12%
BRAF Inhibitor (BRAFi)
12%
Multi-sector
12%
Neoantigen Vaccine
11%
Immune Response
11%
Tumor Antigen
11%
Tumor Subtype
11%
Effector T Cells
11%
Vaccination
11%
Immunology and Microbiology
Neoantigen
66%
T Cell
60%
Immunotherapy
35%
Cytotoxic T-Cell
34%
T-Helper Cell
33%
Salmonella
25%
Listeria monocytogenes
18%
Immunity
17%
Central Nervous System
14%
Immune Response
13%
Antigen Specificity
13%
Infectious Agent
13%
T Cell Receptor
12%
Peptides
12%
Cell Expansion
12%
Germ Cell
12%
Overall Survival
9%
CD4
9%
Tumor-Infiltrating Lymphocytes
9%
Tumor Antigen
8%
Cancer Stem Cell
8%
Brain Tumor Cell Line
8%
CTLA-4
7%
Immune System
7%
Peptide Vaccine
7%
Cytokine
7%
T Cell Proliferation
7%
Listeriosis
6%
Tumor Vaccine
6%
Interleukin 21
6%
Major Histocompatibility Complex
6%
STAT5
6%
Progression Free Survival
6%
Regulatory T Cell
6%
Decision Making
6%
Cell Lineage
6%
Dendritic Cell
6%
Immunoassay
6%
Blood Plasma
6%
Transcription Factor GATA 2
6%
Pembrolizumab
6%
Dynamics
6%
Programmed Death-Ligand 1
6%
Squamous Cell
6%
Interleukin 17
6%
DNA Immunization
6%
B Cell
5%
RNA Sequence
5%
Lymphocyte
5%
ELISPOT
5%
Medicine and Dentistry
Glioblastoma
55%
Immunotherapy
50%
Neoplasm
28%
Melanoma
22%
Radiation Therapy
22%
Ganglioglioma
20%
Tumor Progression
18%
Metastatic Melanoma
17%
Pembrolizumab
15%
T Cell
13%
Intracranial Tumor
13%
Overall Survival
12%
Isocitrate Dehydrogenase
12%
Temozolomide
12%
Malignant Neoplasm
10%
Progression Free Survival
9%
Magnetic Resonance Imaging
8%
Germ Cell
8%
MEK Inhibitor
8%
Targeted Therapy
8%
Medicine
7%
Brain Metastasis
7%
Oligoastrocytoma
7%
Late Effect
7%
Clinical Trial
6%
Diffuse Large B-Cell Lymphoma
6%
Salvage Therapy
6%
Rituximab
6%
Isoetarine
6%
Combined Therapy
6%
Oligodendroglioma
6%
Doxorubicin
6%
Programmed Death-Ligand 1
6%
Treatment Effect
6%
4 Iodo 2,5 Dimethoxyamphetamine
6%
Cell Lineage
6%
Epidermal Growth Factor Receptor
6%
Neuro-Oncology
6%
Cetuximab
6%
B Cell
6%
Infusion
6%
Skin Carcinoma
6%
Immune Checkpoint Blockade
6%
Early Diagnosis
6%
Cancer Stem Cell
6%
Lymphoscintigraphy
6%
Recurrent Infection
6%
Talimogene Laherparepvec
6%
Personalized Medicine
6%
Protein Kinase C
6%
